Vasoplegia After Cardiovascular Procedures—Pathophysiology and Targeted Therapy

Journal of Cardiothoracic and Vascular Anesthesia

Volumn 32, Issue 2, 2018, Pages 1013-1022

  Shaefi, Shahzad ^a   Mittel, Aaron ^b   Klick, John ^c   Evans, Adam ^d   Ivascu, Natalia S ^e   Gutsche, Jacob ^f   Augoustides, John G T ^f  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b Department of Medicine   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

angiotensin II; cardiopulmonary bypass; hydroxocobalamin; methylene blue; nitric oxide; pathophysiology of vasoplegic shock; vasopressin

Indexed keywords

ANGIOTENSIN II; ASCORBIC ACID; CATECHOLAMINE; CORTICOSTEROID; HYDROXOCOBALAMIN; METHYLENE BLUE; TERLIPRESSIN; VASOACTIVE AGENT; VASOPRESSIN;

BLOOD VESSEL TONE; CARDIOVASCULAR PROCEDURE; CARDIOVASCULAR SURGERY; FLUID RESUSCITATION; HUMAN; INCIDENCE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; VASOPLEGIA; CARDIOPULMONARY BYPASS; HEART SURGERY; VASCULAR SURGERY;

ANGIOTENSIN II; CARDIAC SURGICAL PROCEDURES; CARDIOPULMONARY BYPASS; HUMANS; METHYLENE BLUE; RISK FACTORS; VASCULAR SURGICAL PROCEDURES; VASOPLEGIA;

EID: 85043591454     PISSN: 10530770     EISSN: 15328422     Source Type: Journal    
DOI: 10.1053/j.jvca.2017.10.032     Document Type: Review

References (66)

1. Gomes, W.J., Carvalho, A.C., Palma, J.H., et al. Vasoplegic syndrome after open heart surgery. J Cardiovasc Surg 39 (1998), 619–623.
2. Levin, M.A., Lin, H.M., Castillo, J.G., et al. Early on-cardiopulmonary bypass hypotension and other factors associated with vasoplegic syndrome. Circulation 120 (2009), 1664–1671.
3. Mets, B., Michler, R.E., Delphin, E.D., et al. Refractory vasodilation after cardiopulmonary bypass for heart transplantation in recipients on combined amiodarone and angiotensin-converting enzyme inhibitor therapy: A role for vasopressin administration. J Cardiothorac Vasc Anesth 12 (1998), 326–329.
4. Omar, S., Zedan, A., Nugent, K., Cardiac vasoplegia syndrome: Pathophysiology, risk factors and treatment. Am J Med Sci 349 (2015), 80–88.
5. Landry, D.W., Oliver, J.A., The pathogenesis of vasodilatory shock. N Engl J Med 345 (2001), 588–595.
6. Fischer, G.W., Levin, M.A., Vasoplegia during cardiac surgery: Current concepts and management. Semin Thorac Cardiovasc Surg 22 (2010), 140–144.
7. Weis, F., Kilger, E., Beiras-Fernandez, A., et al. Association between vasopressor dependence and early outcome in patients after cardiac surgery. Anaesthesia 61 (2006), 938–942.
8. Szabo, C., Role of poly(ADP-ribose) synthetase activation in the suppression of cellular energetics in response to nitric oxide and peroxynitrite. Biochem Soc Trans 25 (1997), 919–924.
9. Hauser, B., Bracht, H., Matejovic, M., et al. Nitric oxide synthase inhibition in sepsis? Lessons learned from large-animal studies. Anesth Analg 101 (2005), 488–498.
10. Lopez, A., Lorente, J.A., Steingrub, J., et al. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: Effect on survival in patients with septic shock. Critical Care Med 32 (2004), 21–30.
11. Landry, D.W., Levin, H.R., Gallant, E.M., et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 95 (1997), 1122–1125.
12. Wilson, M.F., Brackett, D.J., Tompkins, P., et al. Elevated plasma vasopressin concentrations during endotoxin and E. coli shock. Adv Shock Res 6 (1981), 15–26.
13. Wakatsuki, T., Nakaya, Y., Inoue, I., Vasopressin modulates K(+)-channel activities of cultured smooth muscle cells from porcine coronary artery. Am J Physiol 263 (1992), H491–H496.
14. Umino, T., Kusano, E., Muto, S., et al. AVP inhibits LPS- and IL-1beta-stimulated NO and cGMP via V1 receptor in cultured rat mesangial cells. Am J Physiol 276 (1999), F433–F441.
15. Hall, R.I., Smith, M.S., Rocker, G., The systemic inflammatory response to cardiopulmonary bypass: Pathophysiological, therapeutic, and pharmacological considerations. Anesth Analg 85 (1997), 766–782.
16. Wan, S., LeClerc, J.L., Vincent, J.L., Inflammatory response to cardiopulmonary bypass: Mechanisms involved and possible therapeutic strategies. Chest 112 (1997), 676–692.
17. Kerbaul, F., Guidon, C., Lejeune, P.J., et al. Hyperprocalcitonemia is related to noninfectious postoperative severe systemic inflammatory response syndrome associated with cardiovascular dysfunction after coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth 16 (2002), 47–53.
18. Sundaram, V., Fang, J.C., Gastrointestinal and liver issues in heart failure. Circulation 133 (2016), 1696–1703.
19. Argenziano, M., Chen, J.M., Choudhri, A.F., et al. Management of vasodilatory shock after cardiac surgery: Identification of predisposing factors and use of a novel pressor agent. J Thorac Cardiovasc Surg 116 (1998), 973–980.
20. Colson, P.H., Bernard, C., Struck, J., et al. Post cardiac surgery vasoplegia is associated with high preoperative copeptin plasma concentration. Crit Care, 15, 2011, R255.
21. Angus, D.C., Barnato, A.E., Bell, D., et al. A systematic review and meta-analysis of early goal-directed therapy for septic shock: The ARISE, ProCESS and ProMISe Investigators. Intensive Care Med 41 (2015), 1549–1560.
22. Rhodes, A., Evans, L.E., Alhazzani, W., et al. Surviving Sepsis Campaign: International Guidelines for management of sepsis and septic shock: 2016. Critical Care Med 45 (2015), 486–552.
23. Fuda, G., Denault, A., Deschamps, A., et al. Risk factors involved in central-to-radial arterial pressure gradient during cardiac surgery. Anesth Analg 122 (2016), 624–632.
24. Papadopoulos, G., Sintou, E., Siminelakis, S., et al. Perioperative infusion of low- dose of vasopressin for prevention and management of vasodilatory vasoplegic syndrome in patients undergoing coronary artery bypass grafting: A double-blind randomized study. J Cardiothorac Surg, 5, 2010, 17.
25. Lange, M., Aken, H.V., Westphal, M., Role of vasopressinergic V1 receptor agonists in the treatment of perioperative catecholamine-refractory arterial hypotension. Best Pract Res Clin Anaesthesiol 22 (2008), 369–381.
26. Murphy, G.J., Pike, K., Rogers, C.A., et al. Liberal or restrictive transfusion after cardiac surgery. N Engl J Med 372 (2015), 997–1008.
27. Marik, P.E., Early management of severe sepsis: Concepts and controversies. Chest 145 (2014), 1407–1418.
28. Boyd, J.H., Forbes, J., Nakada, T.A., et al. Fluid resuscitation in septic shock: A positive fluid balance and elevated central venous pressure are associated with increased mortality. Critical Care Med 39 (2011), 259–265.
29. Vieillard-Baron, A., Caille, V., Charron, C., et al. Actual incidence of global left ventricular hypokinesia in adult septic shock. Critical Care Med 36 (2008), 1701–1706.
30. Vincent, J.L., De Backer, D., Circulatory shock. N Engl J Med 369 (2013), 1726–1734.
31. Vail, E., Gershengorn, H.B., Hua, M., et al. Association between US norepinephrine shortage and mortality among patients with septic shock. JAMA 317 (2017), 1433–1442.
32. De Backer, D., Biston, P., Devriendt, J., et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 362 (2010), 779–789.
33. Annane, D., Vignon, P., Renault, A., et al. Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: A randomised trial. Lancet 370 (2007), 676–684.
34. De Backer, D., Aldecoa, C., Njimi, H., et al. Dopamine versus norepinephrine in the treatment of septic shock: A meta-analysis. Crit Care Med 40 (2012), 725–730.
35. Egi, M., Bellomo, R., Langenberg, C., et al. Selecting a vasopressor drug for vasoplegic shock after adult cardiac surgery: A systematic literature review. Ann Thorac Surg 83 (2007), 715–723.
36. Russell, J.A., Walley, K.R., Singer, J., et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 358 (2008), 877–887.
37. Gordon, A.C., Russell, J.A., Walley, K.R., et al. The effects of vasopressin on acute kidney injury in septic shock. Intensive Care Med 36 (2010), 83–91.
38. Gordon, A.C., Mason, A.J., Thirunavukkarasu, N., et al. Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock: The VANISH randomized Clinical Trial. JAMA 316 (2016), 509–518.
39. Morales DL, Garrido MJ, Madigan JD, et al. A double-blind randomized trial: Prophylactic vasopressin reduces hypotension after cardiopulmonary bypass. Ann Thorac Surg;75:926–30.
40. Hajjar, L.A., Vincent, J.L., Barbosa Gomes Galas, F.R., et al. Vasopressin versus norepinephrine in patients with vasoplegic shock after cardiac surgery: The VANCS randomized controlled trial. Anesthesiology 126 (2017), 85–93.
41. Schmidt, H.H., NO., CO and.OH. Endogenous soluble guanylyl cyclase-activating factors. FEBS Lett 307 (1992), 102–107.
42. Shanmugam, G., Vasoplegic syndrome—the role of methylene blue. Eur J Cardiothorac Surg 28 (2005), 705–710.
43. Wolvetang, T., Janse, R., Ter Horst, M., Serotonin syndrome after methylene blue administration during cardiac surgery: A case report and review. J Cardiothorac Vasc Anesth 30 (2016), 1042–1045.
44. Kofidis, T., Struber, M., Wilhelmi, M., et al. Reversal of severe vasoplegia with single-dose methylene blue after heart transplantation. J Thorac Cardiovasc Surg 122 (2001), 823–824.
45. Yiu, P., Robin, J., Pattison, C.W., Reversal of refractory hypotension with single-dose methylene blue after coronary artery bypass surgery. J Thorac Cardiovasc Surg 118 (1999), 195–196.
46. Levin, R.L., Degrange, M.A., Bruno, G.F., et al. Methylene blue reduces mortality and morbidity in vasoplegic patients after cardiac surgery. Ann Thorac Surg 77 (2004), 496–499.
47. Leyh, R.G., Kofidis, T., Struber, M., et al. Methylene blue: The drug of choice for catecholamine-refractory vasoplegia after cardiopulmonary bypass?. J Thorac Cardiovasc Surg 125 (2003), 1426–1431.
48. Maslow, A.D., Stearns, G., Butala, P., et al. The hemodynamic effects of methylene blue when administered at the onset of cardiopulmonary bypass. Anesth Analg 103 (2006), 2–8.
49. Ozal, E., Kuralay, E., Yildirim, V., et al. Preoperative methylene blue administration in patients at high risk for vasoplegic syndrome during cardiac surgery. Ann Thorac Surg 79 (2005), 1615–1619.
50. Mehaffey, J.H., Johnston, L.E., Hawkins, R.B., et al. Methylene blue for vasoplegic syndrome after cardiac operation: Early administration improves survival. Ann Thorac Surg 104 (2017), 36–41.
51. Weiner, M.M., Lin, H.M., Danforth, D., et al. Methylene blue is associated with poor outcomes in vasoplegic shock. J Cardiothorac Vasc Anesth 27 (2013), 1233–1238.
52. Belletti, A., Musu, M., Silvetti, S., et al. Non-adrenergic vasopressors in patients with or at risk for vasodilatory shock: A systematic review and meta-analysis of randomized trials. PloS One, 10, 2015, e0142605.
53. Sprung, C.L., Annane, D., Keh, D., et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med 358 (2008), 111–124.
54. Annane, D., Sebille, V., Charpentier, C., et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 288 (2002), 862–871.
55. Whitlock, R.P., Devereaux, P.J., Teoh, K.H., et al. Methylprednisolone in patients undergoing cardiopulmonary bypass (SIRS): A randomised, double-blind, placebo-controlled trial. Lancet 386 (2015), 1243–1253.
56. Dieleman, J.M., Nierich, A.P., Rosseel, P.M., et al. Intraoperative high-dose dexamethasone for cardiac surgery: A randomized controlled trial. JAMA 308 (2012), 1761–1767.
57. Marik, P.E., Khangoora, V., Rivera, R., et al. Hydrocortisone, vitamin C and thiamine for the treatment of severe sepsis and septic shock: A retrospective before-after study. Chest 151 (2017), 1229–1238.
58. Burnes, M.L., Boettcher, B.T., Woehlck, H.J., et al. Hydroxocobalamin as a rescue treatment for refractory vasoplegic syndrome after prolonged cardiopulmonary bypass. J Cardiothorac Vasc Anesth 31 (2016), 1012–1014.
59. Roderique, J.D., VanDyck, K., Holman, B., et al. The use of high-dose hydroxocobalamin for vasoplegic syndrome. Ann Thorac Surg 97 (2014), 1785–1786.
60. Geraci, M.J., McCoy, S.L., Aquino, M.E., Woman with red urine: Hydroxocobalamin-induced chromaturia. J Emerg Med 43 (2012), e207–e209.
61. Akinosoglou, K., Alexopoulos, D., Use of antiplatelet agents in sepsis: A glimpse into the future. Thromb Res 133 (2014), 131–138.
62. Morelli, A., Ertmer, C., Rehberg, S., et al. Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): A randomized, controlled pilot study. Crit Care, 13, 2009, R130.
63. Morelli, A., Ertmer, C., Lange, M., et al. Effects of short-term simultaneous infusion of dobutamine and terlipressin in patients with septic shock: The DOBUPRESS study. Br J Anaesth 100 (2008), 494–503.
64. Marks, J.A., Pascual, J.L., Selepressin in septic shock: Sharpening the VASST effects of vasopressin?. Crit Care Med 42 (2014), 1747–1748.
65. Chawla, L.S., Busse, L., Brasha-Mitchell, E., et al. Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): A pilot study. Crit Care, 18, 2014, 534.
66. Khanna, A., English, S.W., Wang, X.S., et al. Angiotensin II for the treatment of vasodilatory shock. N Engl J Med 377 (2017), 419–430.